What Is Dihexa? Uses, Benefits, Safety, FDA Status, and Evidence

Medical review note: This article is for educational purposes only and does not provide medical advice. Dihexa is not FDA-approved for human therapeutic use. Products sold online as Dihexa, Dihexa acetate, or “research use only” Dihexa may carry serious safety, quality, and legal risks.

Quick answer

Dihexa is an experimental angiotensin IV-derived compound studied for cognition, synaptogenesis, and neurodegenerative disease models. It is often described as a nootropic peptide or peptidomimetic that may potentiate hepatocyte growth factor, also called HGF, signaling through the c-Met receptor. Animal and laboratory studies suggest Dihexa may improve memory-related outcomes and promote synapse formation, but there is no strong human clinical evidence showing that Dihexa safely improves cognition, treats Alzheimer’s disease, reverses brain aging, or works as a consumer nootropic. Dihexa is not FDA-approved, and FDA says it lacks important safety information on Dihexa acetate, including whether it would cause harm if administered to humans.

Key facts about Dihexa

Question	Answer
What is Dihexa?	An experimental angiotensin IV-derived compound studied for cognition and synapse formation.
Other names	Dihexa acetate, PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic amide.
Peptide class	Angiotensin IV analog / nootropic peptide / peptidomimetic.
Main mechanism	Proposed potentiation of HGF/c-Met signaling, with effects on spinogenesis, synaptogenesis, and memory-related pathways in animal models.
FDA-approved?	No. Dihexa is not an FDA-approved drug.
Main studied uses	Alzheimer’s disease models, cognitive impairment models, synaptogenesis, memory, and neurodegenerative-disease research.
Human evidence level	Very limited to absent. No strong human clinical trial evidence was found for cognitive or therapeutic use.
Animal/lab evidence level	Substantial preclinical evidence in cognition, synaptogenesis, and HGF/c-Met signaling models.
Common online claims	“Nootropic peptide,” “cognitive enhancer,” “synapse builder,” “Alzheimer’s peptide,” “brain repair,” “neuroplasticity booster.”
Sports status	Not found here as specifically named on the WADA prohibited list, but Dihexa is not FDA-approved and athletes should verify current WADA/Global DRO status before use.
Main safety concern	Lack of human safety data, unknown long-term effects, possible HGF/c-Met pathway concerns, FDA-identified lack of safety information, and risks from unapproved online products.

What is Dihexa?

Dihexa is an experimental compound derived from angiotensin IV, a peptide connected to the brain renin-angiotensin system. It was developed as a metabolically stabilized angiotensin IV analog and studied for procognitive and synaptogenic effects.

A PubMed-indexed study on the procognitive and synaptogenic effects of Dihexa reported that Dihexa and related angiotensin IV analogs induced hippocampal spinogenesis and synaptogenesis in experimental models. The full PMC version of the study describes Dihexa as acting through the HGF/c-Met receptor system.

Dihexa is often marketed online as a “cognitive peptide,” “brain-repair peptide,” or “nootropic peptide.” That language is ahead of the evidence.

The key distinction:

Dihexa has interesting preclinical cognition research, but it is not an FDA-approved cognitive drug, Alzheimer’s treatment, or proven nootropic for humans.

How does Dihexa work?

Dihexa is proposed to work through the hepatocyte growth factor/c-Met system.

HGF is a growth factor involved in cell survival, growth, repair, and neural development. The c-Met receptor is the receptor for HGF. Dihexa has been studied as an HGF mimetic or HGF-potentiating compound that may promote synapse formation and memory-related changes in animal models.

A PubMed-indexed review on the brain HGF/c-Met receptor system describes Dihexa as a first-in-class compound that is orally active, penetrates the blood-brain barrier, and facilitates memory consolidation and retrieval in experimental contexts.

In plain English:

Dihexa is being studied because it may enhance synapse formation and memory-related signaling through HGF/c-Met pathways.

But mechanism is not proof.

A proposed synaptogenic mechanism does not prove that Dihexa improves memory, treats dementia, repairs the brain, reverses neurodegeneration, or safely enhances cognition in humans. The quality of evidence depends on controlled human studies, not animal models, lab studies, patents, or nootropic marketing.

What is Dihexa used for?

Dihexa is commonly discussed for memory, cognition, neuroplasticity, Alzheimer’s disease, brain repair, learning, and nootropic enhancement. These uses differ sharply in evidence quality.

Use	Evidence level	What is known	What is not known
Cognitive impairment models	Preclinical	Animal studies suggest Dihexa may improve memory-related performance in experimental models.	Human cognitive benefit is not established.
Synaptogenesis	Preclinical / mechanistic	Lab and animal studies suggest Dihexa may promote spinogenesis and synaptogenesis.	Clinical relevance in humans is unknown.
Alzheimer’s disease	Preclinical	Dihexa has been studied in Alzheimer’s-like animal models and HGF/c-Met research.	It is not an FDA-approved Alzheimer’s treatment.
Parkinson’s disease / neurodegeneration	Theoretical / preclinical	Related angiotensin IV analog research has been discussed for neurodegenerative disease.	No strong human evidence establishes therapeutic benefit.
Nootropic enhancement	Unsupported in humans	Online claims are common.	Safety, dosing, efficacy, and long-term effects in healthy humans are unknown.
Brain repair	Unsupported as a human claim	Mechanistic research discusses neural repair pathways.	Human brain repair claims are not clinically proven.
Online research-use Dihexa	High uncertainty	Sellers may market it as a cognitive peptide.	Quality, identity, sterility, dosing, and safety may be unknown.

What does the research show?

Human evidence

The human evidence for Dihexa is very limited to absent for practical clinical claims.

No strong, published human clinical trial evidence was found showing that Dihexa safely improves cognition, treats Alzheimer’s disease, treats Parkinson’s disease, reverses cognitive decline, or works as a general nootropic.

The practical interpretation:

Dihexa should not be treated as clinically proven for human cognition.

Animal and laboratory evidence

The preclinical evidence is more substantial.

The PubMed-indexed Dihexa study reported procognitive and synaptogenic effects of Dihexa and related angiotensin IV analogs in experimental systems. The PMC full text describes Dihexa as promoting hippocampal spinogenesis and synaptogenesis similar to HGF and reports that certain effects were blocked by an HGF antagonist.

A PMC study on metabolically stabilized angiotensin IV analogs suggested that Dihexa may have therapeutic potential in disorders where augmented synaptic connectivity could be useful, such as Alzheimer’s disease.

A 2021 PMC study reported that Dihexa rescued cognitive impairment and changed molecular pathways in a mouse model.

The practical interpretation:

Dihexa is scientifically interesting in animal and lab models, but preclinical synaptogenesis and memory findings are not the same as proven human efficacy.

Review-level evidence

A PubMed systematic review of angiotensin IV and angiotensin-related cognitive effects found that in models of cognitive deficit, most studies of Ang IV and its analogs reported improved performance on spatial memory tasks.

This supports the general idea that angiotensin IV analogs may have procognitive effects in experimental models. It does not establish Dihexa as a safe human treatment.

Safety evidence

Safety is the biggest unresolved issue.

The Alzheimer’s Drug Discovery Foundation cognitive vitality report on Dihexa states that Dihexa improves cognition and increases synapses in rat models of cognitive dysfunction, but no studies have evaluated its long-term safety, including potential tumorigenic and cancer metastatic effects.

The FDA page on bulk drug substances that may present significant safety risks states that FDA lacks important information regarding safety issues raised by Dihexa acetate, including whether it would cause harm if administered to humans.

The practical interpretation:

The safety uncertainty is not minor. Dihexa’s proposed HGF/c-Met mechanism is exactly why long-term safety questions matter.

Evidence summary

Claim	Evidence verdict	Explanation
“Dihexa is an angiotensin IV-derived compound.”	Supported	Dihexa is described in scientific literature as a metabolically stabilized angiotensin IV analog.
“Dihexa promotes synaptogenesis.”	Supported preclinically	Lab and animal studies suggest effects on spinogenesis and synaptogenesis.
“Dihexa improves memory.”	Supported in animal models	Animal studies show memory-related effects, but human benefit is not established.
“Dihexa treats Alzheimer’s disease.”	Not established	It has preclinical Alzheimer’s-related research, but no FDA-approved Alzheimer’s indication.
“Dihexa is FDA-approved.”	False	Dihexa is not an FDA-approved drug.
“Dihexa is safe because it is a peptide.”	False	FDA says it lacks important safety information on Dihexa acetate.
“Dihexa is a proven nootropic.”	Unsupported in humans	Human cognitive-enhancement evidence is lacking.
“Dihexa rebuilds brain connections in humans.”	Misleading	Synaptogenesis findings are preclinical and should not be translated directly into human claims.
“Research-use Dihexa is clinically proven.”	False	Research-use products are not FDA-approved consumer therapeutic products.

Is Dihexa FDA-approved?

No. Dihexa is not FDA-approved.

The FDA compounding safety-risk page states that FDA lacks important information regarding any safety issues raised by Dihexa acetate, including whether it would cause harm if administered to humans.

The FDA bulk drug substances document notes that Dihexa acetate was removed from category 2 because the nomination was withdrawn, while FDA announced its intent to consult the Pharmacy Compounding Advisory Committee regarding the potential inclusion of Dihexa acetate on the 503A bulks list.

The key distinction:

Dihexa is a research compound with preclinical data, not an FDA-approved prescription medication.

Is Dihexa legal?

Dihexa’s legal status depends on product type, intended use, and jurisdiction, but the practical answer is simple:

Dihexa is not an FDA-approved drug, and online availability does not mean it is legally marketed for human therapeutic use.

Some sellers market Dihexa as a research peptide or nootropic peptide. That does not make it safe, approved, legal, or appropriate for consumer use.

The blunt version:

Buying “research use only” Dihexa from an online seller is not the same as receiving an FDA-approved cognitive medication from a legitimate pharmacy.

Is Dihexa banned in sports?

I did not find Dihexa specifically named on the WADA prohibited list in the sources reviewed here.

However, the WADA Prohibited List includes broad categories, including non-approved substances under S0. Because Dihexa is not FDA-approved and is not an established therapeutic medication, athletes should not assume it is permitted.

The practical advice:

Athletes should check Global DRO, WADA, or USADA before using Dihexa or any investigational peptide/nootropic compound. Online research-use products are especially high-risk.

Safety and side effects

Dihexa should not be treated as a harmless nootropic.

Possible or theoretical concerns include:

Unknown long-term human safety
Unknown human dosing
Unknown effects from chronic HGF/c-Met pathway modulation
Potential tumorigenic or cancer-metastatic concerns that have not been adequately evaluated
Neurological side effects that have not been systematically studied in humans
Product-quality risk from online sellers
Mislabeling
Peptide-related impurities
Sterility risk for injectable products
Unknown oral, intranasal, injectable, or topical risk profiles
Drug-interaction uncertainty

The most important safety issue is that human safety evidence is inadequate.

FDA states that it lacks important safety information on Dihexa acetate, including whether it would cause harm if administered to humans. The Alzheimer’s Drug Discovery Foundation report also highlights that long-term safety, including potential tumorigenic and cancer-metastatic effects, has not been evaluated.

A serious evaluation of Dihexa should separate preclinical research from consumer nootropic use.

Dihexa vs similar nootropic peptides and compounds

Compound	Category	Main difference
Dihexa	Angiotensin IV analog / HGF-c-Met-related compound	Studied for synaptogenesis and cognition in preclinical models; not FDA-approved.
Semax	ACTH-derived nootropic peptide	Different mechanism and regulatory history; not the same as Dihexa.
Selank	Tuftsin-related anxiolytic/nootropic peptide	Different mechanism and evidence base.
Cerebrolysin	Peptide mixture	Injectable neurotrophic peptide mixture used in some countries, not the same as Dihexa.
BDNF-related compounds	Neurotrophic pathway agents	Different targets; Dihexa is mainly discussed through HGF/c-Met signaling.
Fosgonimeton	HGF/MET pathway drug candidate	A related clinical-development direction, but not the same as consumer Dihexa products.
Modafinil	Wakefulness-promoting prescription drug	FDA-approved for specific sleep disorders, not a peptide and not a synaptogenic HGF/c-Met compound.

The key distinction:

Dihexa belongs in the experimental neurotrophic/nootropic research category. It is not a standard peptide therapy, GLP-1 drug, repair peptide, or FDA-approved cognitive medication.

Why is Dihexa sold as “research use only”?

Some online sellers use “research use only” language to sell Dihexa outside normal drug-approval channels.

That label is not a trust signal.

A serious reader should understand this distinction:

Product type	What it means
Laboratory Dihexa	Research compound used in controlled experimental settings.
FDA-approved Dihexa	Does not currently exist.
Compounded Dihexa acetate	FDA has stated it lacks important safety information and is reviewing compounding-list issues.
Research-use Dihexa	Not an FDA-approved consumer therapeutic product.
Online nootropic Dihexa	Higher risk for identity, purity, dosing, formulation, and safety problems.

How to evaluate Dihexa claims online

Claim	What to verify
“FDA-approved Dihexa”	False. Dihexa is not FDA-approved.
“Clinically proven nootropic”	Look for controlled human trials, not animal memory studies.
“Rebuilds brain connections”	Check whether the evidence is human clinical evidence or preclinical synaptogenesis data.
“Treats Alzheimer’s disease”	False as an approved claim. Dihexa is not an FDA-approved Alzheimer’s medication.
“Safe for long-term use”	Unsupported. Long-term human safety has not been established.
“No cancer risk”	Not proven. HGF/c-Met pathway concerns require serious long-term safety evaluation.
“Research use only”	This does not mean safe, legal, approved, or appropriate for human use.
“Orally active and brain-penetrant”	This is based on preclinical research and does not prove human clinical benefit.
“Third-party tested”	Ask for batch-specific HPLC, LC-MS, identity, purity, residual solvent, microbial, and stability data.

Bottom line

Dihexa is an experimental angiotensin IV-derived compound studied mostly in animal and laboratory models for cognition, synaptogenesis, and HGF/c-Met signaling. The preclinical evidence is scientifically interesting, but Dihexa has not been proven safe or effective as a human cognitive enhancer, Alzheimer’s treatment, brain-repair therapy, or nootropic supplement.

The most defensible conclusion is:

Dihexa is a high-uncertainty research compound, not a consumer peptide. It is not FDA-approved, lacks strong human clinical evidence, and has major unresolved safety questions, especially around long-term HGF/c-Met pathway modulation and unknown human exposure risks.

FAQ

What is Dihexa?

Dihexa is an experimental angiotensin IV-derived compound studied for cognition, synaptogenesis, and HGF/c-Met signaling in animal and laboratory models.

What does Dihexa do?

Dihexa is proposed to potentiate HGF/c-Met signaling and promote spinogenesis and synaptogenesis in preclinical models. This does not prove it improves cognition in humans.

Is Dihexa FDA-approved?

No. Dihexa is not FDA-approved. FDA says it lacks important safety information on Dihexa acetate, including whether it would cause harm if administered to humans.

Does Dihexa improve memory?

Dihexa has shown memory-related effects in animal models, but there is no strong human clinical evidence proving it improves memory in people.

Does Dihexa treat Alzheimer’s disease?

No. Dihexa is not an FDA-approved Alzheimer’s treatment. It has been studied in Alzheimer’s-related preclinical models, but human therapeutic benefit is not established.

Is Dihexa a nootropic?

Dihexa is often marketed as a nootropic peptide, but that marketing goes beyond the evidence. It is better described as an experimental neurotrophic research compound.

Is Dihexa safe?

Dihexa does not have enough human safety data to call it safe. FDA says important safety information is lacking, and long-term concerns such as possible tumorigenic or cancer-metastatic effects have not been adequately evaluated.

Is Dihexa legal?

Dihexa is not an FDA-approved drug. Online sales as a research compound do not mean it is legally marketed for human therapeutic use.

Is Dihexa banned in sports?

I did not find Dihexa specifically named on the WADA prohibited list in the sources reviewed here. Athletes should verify current status with WADA, USADA, or Global DRO before use because investigational substances can create anti-doping risk.

Why do sellers call Dihexa “research use only”?

Sellers often use “research use only” language because Dihexa is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically proven.

What is the biggest risk with Dihexa?

The biggest risk is using an experimental compound with no strong human clinical evidence and unresolved long-term safety questions, especially around HGF/c-Met pathway modulation, unknown dosing, and online product quality.

Sources

Frequently asked questions

What is Dihexa?

Dihexa is an experimental angiotensin IV-derived compound studied for cognition, synaptogenesis, and HGF/c-Met signaling in animal and laboratory models.

Is Dihexa FDA-approved?

No. Dihexa is not FDA-approved. FDA says it lacks important safety information on Dihexa acetate, including whether it would cause harm if administered to humans.

Does Dihexa improve memory?

Dihexa has shown memory-related effects in animal models, but there is no strong human clinical evidence proving it improves memory in people.

Does Dihexa treat Alzheimer's disease?

No. Dihexa is not an FDA-approved Alzheimer's treatment. It has been studied in Alzheimer's-related preclinical models, but human therapeutic benefit is not established.

Is Dihexa safe?

Is Dihexa banned in sports?

No official WADA source was found here specifically naming Dihexa as prohibited. Athletes should verify current status with WADA, USADA, or Global DRO before use because investigational substances can create anti-doping risk.

Sources

[1]
PubMed: The procognitive and synaptogenic effects of angiotensin IV-derived peptides
Preclinical
[2]
PMC: The procognitive and synaptogenic effects of angiotensin IV-derived peptides
Preclinical
[3]
PubMed: The Brain HGF/c-Met Receptor System as a Target for Alzheimer's Disease
Review
[4]
PMC: AngIV-Analog Dihexa Rescues Cognitive Impairment
Preclinical
[5]
PMC: Evaluation of Metabolically Stabilized Angiotensin IV Analogs
Preclinical
[6]
PubMed: Cognitive benefits of Angiotensin IV and Angiotensin-(1-7)
Systematic Review
[7]
PMC: Cognitive benefits of Angiotensin IV and Angiotensin-(1-7)
Systematic Review
[8]
Alzheimer's Drug Discovery Foundation: Dihexa Cognitive Vitality Report
Evidence Review
[9]
FDA: Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
Regulatory
[10]
FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
Regulatory
[11]
WADA: Prohibited List
Anti Doping

Last updated May 9, 2026